Hepatocellular Carcinoma in Children

Part of the Clinical Gastroenterology book series (CG)


Hepatocellular carcinoma (HCC) is the second most common malignant liver tumor in children after hepatoblastoma (HB) and accounts for approximately 0.3% of all pediatric malignancies [1]. The age-adjusted incidence rate of HCC in the United States in children is 0.41 (0.24–0.65) per 1,000,000 population, with no gender predominance [1]. Children with HCC may present at any age, although the incidence is highest between the ages of 10–19 years [1–3].





American Joint Committee on Cancer


Children’s Oncology Group


Familial adenomatous polyposis


Fibrolamellar HCC


Glycogen storage disease type 1




Hepatocellular carcinoma


Hepatitis B virus


Hepatitis C virus


Hereditary tyrosinemia type 1


Lectin-reactive alpha-fetoprotein


Orthotopic liver transplantation


Pretreatment extent of disease


Progressive familial intrahepatic cholestasis


Societé Internationale d’Oncologie Pédiatrique


  1. 1.
    Darbari A, Sabin KM, Shapiro CN, Schwarz KB. Epidemiology of primary hepatic malignancies in U.S. children. Hepatology. 2003;38:560–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Laiq Z, Bishop JA, Ali SZ. Liver lesions in children and adolescents: Cytopathologic analysis and clinical correlates in 44 cases. Diagn Cytopathol 2011 Feb 9. doi:10.1002/dc.21587. [Epub ahead of print].Google Scholar
  3. 3.
    Meyers RL. Tumors of the liver in children. Surg Oncol. 2007;16:195–203.PubMedCrossRefGoogle Scholar
  4. 4.
    Wu TC, Tong MJ, Hwang B, Lee SD, Hu MM. Primary hepatocellular carcinoma and hepatitis B infection during childhood. Hepatology. 1987;7:46–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Lanier AP, Holck P, Ehrsam DG, Key C. Childhood cancer among Alaska Natives. Pediatrics. 2003;112:e396.PubMedCrossRefGoogle Scholar
  6. 6.
    Tajiri H, Tanaka H, Brooks S, Takano T. Reduction of hepatocellular carcinoma in childhood after introduction of selective vaccination against hepatitis B virus for infants born to HBV carrier mothers. Cancer Causes Control 2011;22(3):523–7.Google Scholar
  7. 7.
    Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med. 1997;336:1855–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Chang MH, Shau WY, Chen CJ, Wu TC, Kong MS, Liang DC, et al. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. J Am Med Assoc. 2000;284:3040–2.CrossRefGoogle Scholar
  9. 9.
    Davison SM, Mieli-Vergani G, Sira J, Kelly DA. Perinatal hepatitis C virus infection: diagnosis and management. Arch Dis Child. 2006;91:781–5.PubMedCrossRefGoogle Scholar
  10. 10.
    Mohan P, Colvin C, Glymph C, Chandra RR, Kleiner DE, Patel KM, et al. Clinical spectrum and histopathologic features of chronic hepatitis C infection in children. J Pediatr. 2007;150:168–74.PubMedCrossRefGoogle Scholar
  11. 11.
    Strickland DK, Jenkins JJ, Hudson MM. Hepatitis C infection and hepatocellular carcinoma after treatment of childhood cancer. J Pediatr Hematol Oncol. 2001;23:527–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Castellino S, Lensing S, Riely C, Rai SN, Davila R, Hayden RT, et al. The epidemiology of chronic hepatitis C infection in survivors of childhood cancer: an update of the St Jude Children’s Research Hospital hepatitis C seropositive cohort. Blood. 2004;103:2460–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Weinberg AG, Mize CE, Worthen HG. The occurrence of hepatoma in the chronic form of hereditary tyrosinemia. J Pediatr. 1976;88:434–8.PubMedCrossRefGoogle Scholar
  14. 14.
    van Spronsen FJ, Thomasse Y, Smit GP, Leonard JV, Clayton PT, Fidler V, et al. Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment. Hepatology. 1994;20:1187–91.PubMedCrossRefGoogle Scholar
  15. 15.
    Masurel-Paulet A, Poggi-Bach J, Rolland MO, Bernard O, Guffon N, Dobbelaere D, et al. NTBC treatment in tyrosinaemia type I: long-term outcome in French patients. J Inherit Metab Dis. 2008;31:81–7.PubMedCrossRefGoogle Scholar
  16. 16.
    van Spronsen FJ, Bijleveld CM, van Maldegem BT, Wijburg FA. Hepatocellular carcinoma in hereditary tyrosinemia type I despite 2-(2 nitro-4-3 trifluoro- methylbenzoyl)-1, 3-cyclohexanedione treatment. J Pediatr Gastroenterol Nutr. 2005;40:90–3.PubMedCrossRefGoogle Scholar
  17. 17.
    Perlmutter DH. Pathogenesis of chronic liver injury and hepatocellular carcinoma in alpha-1-antitrypsin deficiency. Pediatr Res. 2006;60:233–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Arnon R, Kerkar N, Davis MK, Anand R, Yin W, Gonzalez-Peralta RP. Liver transplantation in children with metabolic diseases: the studies of pediatric liver transplantation experience. Pediatr Transplant. 2010;14:796–805.PubMedCrossRefGoogle Scholar
  19. 19.
    Carlson J, Eriksson S. Chronic ‘cryptogenic’ liver disease and malignant hepatoma in intermediate alpha 1-antitrypsin deficiency identified by a Pi Z-specific monoclonal antibody. Scand J Gastroenterol. 1985;20:835–42.PubMedCrossRefGoogle Scholar
  20. 20.
    Zhou H, Fischer HP. Liver carcinoma in PiZ alpha-1-antitrypsin deficiency. Am J Surg Pathol. 1998;22:742–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Elzouki AN, Eriksson S. Risk of hepatobiliary disease in adults with severe alpha 1-antitrypsin deficiency (PiZZ): is chronic viral hepatitis B or C an additional risk factor for cirrhosis and hepatocellular carcinoma? Eur J Gastroenterol Hepatol. 1996;8:989–94.PubMedCrossRefGoogle Scholar
  22. 22.
    Bhadri VA, Stormon MO, Arbuckle S, Lam AH, Gaskin KJ, Shun A. Hepatocellular carcinoma in children with Alagille syndrome. J Pediatr Gastroenterol Nutr. 2005;41:676–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Kaufman SS, Wood RP, Shaw Jr BW, Markin RS, Gridelli B, Vanderhoof JA. Hepatocarcinoma in a child with the Alagille syndrome. Am J Dis Child. 1987;141:698–700.PubMedGoogle Scholar
  24. 24.
    McDaniell R, Warthen DM, Sanchez-Lara PA, Pai A, Krantz ID, Piccoli DA, et al. NOTCH2 mutations cause Alagille syndrome, a heterogeneous disorder of the notch signaling pathway. Am J Hum Genet. 2006;79:169–73.PubMedCrossRefGoogle Scholar
  25. 25.
    Yao Z, Mishra L. Cancer stem cells and hepatocellular carcinoma. Cancer Biol Ther. 2009;8:1691–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Rake JP, Visser G, Labrune P, Leonard JV, Ullrich K, Smit GP. Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr. 2002;161 Suppl 1:S20–34.PubMedGoogle Scholar
  27. 27.
    Farges O, Dokmak S. Malignant transformation of liver adenoma: an analysis of the literature. Dig Surg. 2010;27:32–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Tward AD, Jones KD, Yant S, Cheung ST, Fan ST, Chen X, et al. Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc Natl Acad Sci USA. 2007;104:14771–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Franco LM, Krishnamurthy V, Bali D, Weinstein DA, Arn P, Clary B, et al. Hepatocellular carcinoma in glycogen storage disease type Ia: a case series. J Inherit Metab Dis. 2005;28:153–62.PubMedCrossRefGoogle Scholar
  30. 30.
    Brunati A, Feruzi Z, Sokal E, Smets F, Fervaille C, Gosseye S, et al. Early occurrence of hepatocellular carcinoma in biliary atresia treated by liver transplantation. Pediatr Transplant. 2007;11:117–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Tatekawa Y, Asonuma K, Uemoto S, Inomata Y, Tanaka K. Liver transplantation for biliary atresia associated with malignant hepatic tumors. J Pediatr Surg. 2001;36:436–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Iida T, Zendejas IR, Kayler LK, Magliocca JF, Kim RD, Hemming AW, et al. Hepatocellular carcinoma in a 10-month-old biliary atresia child. Pediatr Transplant. 2009;13:1048–9.PubMedCrossRefGoogle Scholar
  33. 33.
    Starzl TE, Giles G, Lilly JR, Takagi H, Martineau G, Schroter G, et al. Indications for orthotopic liver transplantation: with particular reference to hepatomas, biliary atresia, cirrhosis, Wilson’s disease and serum hepatitis. Transplant Proc. 1971;3:308–12.PubMedGoogle Scholar
  34. 34.
    Strautnieks SS, Bull LN, Knisely AS, Kocoshis SA, Dahl N, Arnell H, et al. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet. 1998;20:233–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Knisely AS, Strautnieks SS, Meier Y, Stieger B, Byrne JA, Portmann BC, et al. Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency. Hepatology. 2006;44:478–86.PubMedCrossRefGoogle Scholar
  36. 36.
    Bodmer WF, Bailey CJ, Bodmer J, Bussey HJ, Ellis A, Gorman P, et al. Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature. 1987;328:614–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Giardiello FM, Offerhaus GJ, Krush AJ, Booker SV, Tersmette AC, Mulder JW, et al. Risk of hepatoblastoma in familial adenomatous polyposis. J Pediatr. 1991;119:766–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Hughes LJ, Michels VV. Risk of hepatoblastoma in familial adenomatous polyposis. Am J Med Genet. 1992;43:1023–5.PubMedCrossRefGoogle Scholar
  39. 39.
    Su LK, Abdalla EK, Law CH, Kohlmann W, Rashid A, Vauthey JN. Biallelic inactivation of the APC gene is associated with hepatocellular carcinoma in familial adenomatous polyposis coli. Cancer. 2001;92:332–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Gruner BA, DeNapoli TS, Andrews W, Tomlinson G, Bowman L, Weitman SD. Hepatocellular carcinoma in children associated with Gardner syndrome or familial adenomatous polyposis. J Pediatr Hematol Oncol. 1998;20:274–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Thompson MD, Monga SP. WNT/beta-catenin signaling in liver health and disease. Hepatology. 2007;45:1298–305.PubMedCrossRefGoogle Scholar
  42. 42.
    Sun Z, Lu P, Gail MH, Pee D, Zhang Q, Ming L, et al. Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1. Hepatology. 1999;30:379–83.PubMedCrossRefGoogle Scholar
  43. 43.
    Liu J, Waalkes MP. Liver is a target of arsenic carcinogenesis. Toxicol Sci. 2008;105:24–32.PubMedCrossRefGoogle Scholar
  44. 44.
    Liaw J, Marshall G, Yuan Y, Ferreccio C, Steinmaus C, Smith AH. Increased childhood liver cancer mortality and arsenic in drinking water in northern Chile. Cancer Epidemiol Biomarkers Prev. 2008;17:1982–7.PubMedCrossRefGoogle Scholar
  45. 45.
    Czauderna P. Adult type vs. Childhood hepatocellular carcinoma—are they the same or different lesions? Biology, natural history, prognosis, and treatment. Med Pediatr Oncol. 2002;39:519–23.PubMedCrossRefGoogle Scholar
  46. 46.
    Di Bisceglie AM, Rustgi VK, Hoofnagle JH, Dusheiko GM, Lotze MT. NIH conference. Hepatocellular carcinoma. Ann Intern Med. 1988;108:390–401.PubMedGoogle Scholar
  47. 47.
    Kew MC. Hepatocellular carcinoma with and without cirrhosis. A comparison in southern African blacks. Gastroenterology. 1989;97:136–9.PubMedGoogle Scholar
  48. 48.
    Prokurat A, Kluge P, Kosciesza A, Perek D, Kappeler A, Zimmermann A. Transitional liver cell tumors (TLCT) in older children and adolescents: a novel group of aggressive hepatic tumors expressing beta-catenin. Med Pediatr Oncol. 2002;39:510–8.PubMedCrossRefGoogle Scholar
  49. 49.
    Stocker JT, Husain AN, Dehner LP, Chandra RS. Pediatric pathology. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 773.Google Scholar
  50. 50.
    Edmondson HA. Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood. AMA J Dis Child. 1956;91:168–86.PubMedGoogle Scholar
  51. 51.
    Berman MA, Burnham JA, Sheahan DG. Fibrolamellar carcinoma of the liver: an immunohistochemical study of nineteen cases and a review of the literature. Hum Pathol. 1988;19:784–94.PubMedCrossRefGoogle Scholar
  52. 52.
    El Serag HB, Davila JA. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology. 2004;39:798–803.PubMedCrossRefGoogle Scholar
  53. 53.
    Katzenstein HM, Krailo MD, Malogolowkin MH, Ortega JA, Qu W, Douglass EC, et al. Fibrolamellar hepatocellular carcinoma in children and adolescents. Cancer. 2003;97:2006–12.PubMedCrossRefGoogle Scholar
  54. 54.
    Stipa F, Yoon SS, Liau KH, Fong Y, Jarnagin WR, D’Angelica M, et al. Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer. 2006;106:1331–8.PubMedCrossRefGoogle Scholar
  55. 55.
    Craig JR, Peters RL, Edmondson HA, Omata M. Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features. Cancer. 1980;46:372–9.PubMedCrossRefGoogle Scholar
  56. 56.
    Cheah PL, Looi LM, Lin HP, Yap SF. Childhood primary hepatocellular carcinoma and hepatitis B virus infection. Cancer. 1990;65:174–6.PubMedCrossRefGoogle Scholar
  57. 57.
    Chang MH, Chen DS, Hsu HC, Hsu HY, Lee CY. Maternal transmission of hepatitis B virus in childhood hepatocellular carcinoma. Cancer. 1989;64:2377–80.PubMedCrossRefGoogle Scholar
  58. 58.
    Kaposi-Novak P, Lee JS, Gomez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest. 2006;116:1582–95.PubMedCrossRefGoogle Scholar
  59. 59.
    Park WS, Dong SM, Kim SY, Na EY, Shin MS, Pi JH, et al. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res. 1999;59:307–10.PubMedGoogle Scholar
  60. 60.
    Peng SY, Chou SP, Hsu HC. Association of downregulation of cyclin D1 and of overexpression of cyclin E with p53 mutation, high tumor grade and poor prognosis in hepatocellular carcinoma. J Hepatol. 1998;29:281–9.PubMedCrossRefGoogle Scholar
  61. 61.
    Kim H, Lee MJ, Kim MR, Chung IP, Kim YM, Lee JY, et al. Expression of cyclin D1, cyclin E, cdk4 and loss of heterozygosity of 8p, 13q, 17p in hepatocellular carcinoma: comparison study of childhood and adult hepatocellular carcinoma. Liver. 2000;20:173–8.PubMedCrossRefGoogle Scholar
  62. 62.
    Yu SB, Kim HY, Eo H, Won JK, Jung SE, Park KW, et al. Clinical characteristics and prognosis of pediatric hepatocellular carcinoma. World J Surg. 2006;30:43–50.PubMedCrossRefGoogle Scholar
  63. 63.
    Bellani FF, Massimino M. Liver tumors in childhood: epidemiology and clinics. J Surg Oncol Suppl. 1993;3:119–21.PubMedCrossRefGoogle Scholar
  64. 64.
    Czauderna P, Mackinlay G, Perilongo G, Brown J, Shafford E, Aronson D, et al. Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group. J Clin Oncol. 2002;20:2798–804.PubMedCrossRefGoogle Scholar
  65. 65.
    Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–36.PubMedCrossRefGoogle Scholar
  66. 66.
    DeBaun MR, Tucker MA. Risk of cancer during the first four years of life in children from The Beckwith-Wiedemann Syndrome Registry. J Pediatr. 1998;132:398–400.PubMedCrossRefGoogle Scholar
  67. 67.
    Katzenstein HM, Krailo MD, Malogolowkin MH, Ortega JA, Liu-Mares W, Douglass EC, et al. Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children’s Cancer Group intergroup study. J Clin Oncol. 2002;20:2789–97.PubMedCrossRefGoogle Scholar
  68. 68.
    Taketa K, Endo Y, Sekiya C, Tanikawa K, Koji T, Taga H, et al. A collaborative study for the evaluation of lectin-reactive alpha-fetoproteins in early detection of hepatocellular carcinoma. Cancer Res. 1993;53:5419–23.PubMedGoogle Scholar
  69. 69.
    Baumann U, Duhme V, Auth MK, McKiernan PJ, Holme E. Lectin-reactive alpha-fetoprotein in patients with tyrosinemia type I and hepatocellular carcinoma. J Pediatr Gastroenterol Nutr. 2006;43:77–82.PubMedCrossRefGoogle Scholar
  70. 70.
    Saar B, Kellner-Weldon F. Radiological diagnosis of hepatocellular carcinoma. Liver Int. 2008;28:189–99.PubMedCrossRefGoogle Scholar
  71. 71.
    Marrero JA, Hussain HK, Nghiem HV, Umar R, Fontana RJ, Lok AS. Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transplant. 2005;11:281–9.CrossRefGoogle Scholar
  72. 72.
    Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–9.PubMedCrossRefGoogle Scholar
  73. 73.
    Shah SA, Cleary SP, Wei AC, Yang I, Taylor BR, Hemming AW, et al. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery. 2007;141:330–9.PubMedCrossRefGoogle Scholar
  74. 74.
    Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35–43.PubMedCrossRefGoogle Scholar
  75. 75.
    Roebuck DJ, Aronson D, Clapuyt P, Czauderna P, de Ville DG, Gauthier F, et al. PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group. Pediatr Radiol. 2007;37:123–32.PubMedCrossRefGoogle Scholar
  76. 76.
    Brown J, Perilongo G, Shafford E, Keeling J, Pritchard J, Brock P, et al. Pretreatment prognostic factors for children with hepatoblastoma—results from the International Society of Paediatric Oncology (SIOP) study SIOPEL 1. Eur J Cancer. 2000;36:1418–25.PubMedCrossRefGoogle Scholar
  77. 77.
    Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. J Am Med Assoc. 2010;304:2154–60.CrossRefGoogle Scholar
  78. 78.
    DeVita VTJ TSLaSAR. Cancer: principles & practice of oncology. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2008.Google Scholar
  79. 79.
    Von Schweinitz D. International Society of Paediatric Oncology, SIOP XXXVII Annual Congress Meeting: Abstracts. Pediatr Blood Cancer 2005;45:371.Google Scholar
  80. 80.
    Iyer R, Fetterly G, Lugade A, Thanavala Y. Sorafenib: a clinical and pharmacologic review. Expert Opin Pharmacother. 2010;11:1943–55.PubMedCrossRefGoogle Scholar
  81. 81.
    Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.PubMedCrossRefGoogle Scholar
  82. 82.
    Phase III Randomized Study of Sorafenib Tosylate With Versus Without Doxorubicin Hydrochloride in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma. http://www.cancer.gov/clinicaltrials/search/view?cdrid=659348&version=HealthProfessional&protocolsearchid=8987722. 2011. 31-3-2011 Jul 1;56(7):1013–8.
  83. 83.
    Keir ST, Maris JM, Lock R, Kolb EA, Gorlick R, Carol H, et al. Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2010;55:1126–33.PubMedCrossRefGoogle Scholar
  84. 84.
    Otte JB. Should the selection of children with hepatocellular carcinoma be based on Milan criteria? Pediatr Transplant. 2008;12:1–3.PubMedCrossRefGoogle Scholar
  85. 85.
    Beaunoyer M, Vanatta JM, Ogihara M, Strichartz D, Dahl G, Berquist WE, et al. Outcomes of transplantation in children with primary hepatic malignancy. Pediatr Transplant. 2007;11:655–60.PubMedCrossRefGoogle Scholar
  86. 86.
    Ismail H, Broniszczak D, Kalicinski P, Markiewicz-Kijewska M, Teisseyre J, Stefanowicz M, et al. Liver transplantation in children with hepatocellular carcinoma. Do Milan criteria apply to pediatric patients? Pediatr Transplant. 2009;13:682–92.PubMedCrossRefGoogle Scholar
  87. 87.
    Kosola S, Lauronen J, Sairanen H, Heikinheimo M, Jalanko H, Pakarinen M. High survival rates after liver transplantation for hepatoblastoma and hepatocellular carcinoma. Pediatr Transplant. 2010;14:646–50.PubMedCrossRefGoogle Scholar
  88. 88.
    Gupta AA, Gerstle JT, Ng V, Wong A, Fecteau A, Malogolowkin MH et al. Critical review of controversial issues in the management of advanced pediatric liver tumors. Pediatr Blood Cancer. 2011;56(7):1013–8.Google Scholar
  89. 89.
    Austin MT, Leys CM, Feurer ID, Lovvorn III HN, O’Neill Jr JA, Pinson CW, et al. Liver transplantation for childhood hepatic malignancy: a review of the United Network for Organ Sharing (UNOS) database. J Pediatr Surg. 2006;41:182–6.PubMedCrossRefGoogle Scholar
  90. 90.
    Otte JB, Meyers R. PLUTO first report. Pediatr Transplant. 2010;14:830–5.PubMedCrossRefGoogle Scholar
  91. 91.
    Otte JB. Progress in the surgical treatment of malignant liver tumors in children. Cancer Treat Rev. 2010;36:360–71.PubMedCrossRefGoogle Scholar
  92. 92.
    Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–9.PubMedCrossRefGoogle Scholar
  93. 93.
    Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164–71.PubMedCrossRefGoogle Scholar
  94. 94.
    Kudo M. Radiofrequency ablation for hepatocellular carcinoma: updated review in 2010. Oncology. 2010;78 Suppl 1:113–24.PubMedCrossRefGoogle Scholar
  95. 95.
    Lau WY, Lai EC. The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review. Ann Surg. 2009;249:20–5.PubMedCrossRefGoogle Scholar
  96. 96.
    Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology. 2009;49:453–9.PubMedCrossRefGoogle Scholar
  97. 97.
    Ye J, Shu Q, Li M, Jiang TA. Percutaneous radiofrequency ablation for treatment of hepatoblastoma recurrence. Pediatr Radiol. 2008;38:1021–3.PubMedCrossRefGoogle Scholar
  98. 98.
    Hoffer FA, Daw NC, Xiong X, Anghelescu D, Krasin M, Yan X, et al. A phase 1/pilot study of radiofrequency ablation for the treatment of recurrent pediatric solid tumors. Cancer. 2009;115:1328–37.PubMedCrossRefGoogle Scholar
  99. 99.
    Sasaki Y, Imaoka S, Ishiguro S, Nakano H, Kasugai H, Fujita M, et al. Clinical features of small hepatocellular carcinomas as assessed by histologic grades. Surgery. 1996;119:252–60.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Christiane Sokollik
    • 1
  • Abha Gupta
    • 2
  • Simon C. Ling
    • 1
  1. 1.Division of Gastroenterology, Hepatology and Nutrition, Department of PaediatricsUniversity of Toronto, The Hospital for Sick ChildrenTorontoCanada
  2. 2.Division of Hematology/Oncology, Department of PaediatricsUniversity of Toronto, The Hospital for Sick ChildrenTorontoCanada

Personalised recommendations